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B19 parvovirus is pathogenic in humans. The virus propagates in the bone marrow, where it is cytotoxic to erythroid 
progenitor ceils. Antibodies appear in blood after infection and neutralize virus in vitro; infection appears to confer lasting 
immunity. The predominant immune response on immunoblot is to the minor capsid protein (VP1), which differs from the 
major capsid protein (VP2) by an additional 227 amino acids. We previously demonstrated that antisera directed to a fusion 
protein containing this unique region or to more limited fusion peptidee of 50-100 amino acids each neutralized virus. In 
the current work, we tested synthetic peptides of about 20 amino acids derived from the VP1 unique region for their ability 
to elicit a neutralizing antibody response in rabbits. Individual peptides were covalently linked to a lysine core to produce 
a multivalent antigen. Animals produced antibodies to all 13 synthetic peptides, as determined by ELISA. At 12 weeks, 
animals injected with one of three peptides --two from the far amino terminus and the third from the center of the unique 
region -- had produced antibodies that completely neutralized virus; by 16 weeks, antisera elicited with another four peptides 
also were effective. In summary, we identified regions containing neutralizing epitopee within the first 80 amino acids and 
amino acids 148-205 of the unique region. Our data suggest hat synthetic peptides might be useful vaccine reagents for 
protection against parvovirus infection in humans. © 1995 Academic Press, inc. 
B19 parvovirus is the only member of the large Parvovi- 
ridae family to cause disease in humans (Young, 1993). 
The identified target of infection is the erythroid progeni- 
tor celt of the marrow. Destruction of erythroid precursors 
in persons with underlying hemolysis results in transient 
aplastic crisis (Serjeant et aL, 1981), in immunosup- 
pressed patients, chronic anemia (Kurtzman et aL, 1987), 
and in the midtrimester infant, hydrops fetalis (Anderson 
et aL, 1988; Anand et aL, 1987), or congenital anemia 
(Brown et al., 1994). In normal persons, virus propagates 
in the marrow, but symptoms result from immune com- 
plex deposition, in the skin of children as fifth disease 
(Anderson and Cherry, 1987) and in the joints of adults 
as a rheumatic syndrome (White etaL, 1985; Simpson et 
aL, 1984). B19 parvovirus also has been associated with 
myocarditis (Saint-Martin eta/., 1990) and vasculitis (Fin- 
kel et aL, 1994). 
Antibody formation accompanies acute parvovirus in- 
fection (Cohen et al., 1983; Anderson et aL, 1985), and 
the humoral immune response appears to be dominant 
in limiting and preventing infection. The presence of spe- 
cific IgG to B19 parvovirus has been presumed to indi- 
cate life-long immunity (Erdman et aL, 1991). Administra- 
tion of commercial immunoglobulin terminates persistent 
infection (Kurtzman et aL, 1989b; Frickhofen et aL, 1990). 
~To whom correspondence and reprint requests should be ad- 
dressed. 
A T cell response to B19 parvovirus, either lymphocyte 
proliferation (Kurtzman et aL, 1989a) or lymphokine pro- 
duction (Nistic6 and Young, unpublished data), has not 
been detected in vitro. 
The single-stranded DNA genome of B19 parvovirus 
encodes two structural proteins, the major capsid (VP2) 
and minor capsid (VP1) proteins (Shade et al., 1986; 
Cotmore eta/., 1986; Ozawa et al., 1987). VP1, of molecu- 
lar weight 83 kDa, has an identical amino-acid sequence 
to VP2 protein, 58 kDa, except for an additional 227 amino 
acids at its amino-terminus. Sixty copies of the capsid 
proteins assemble into a capsid which naturally contains 
about 95% VP2 and 5% VP1 (Ozawa and Young, 1987). 
By X-ray crystallography, B19 parvovirus capsids have a 
geometry similar to that of other icosahedral particles 
(Agbandje et aL, 1994). 
Although VP2 predominates in the capsid, VP1 is im- 
portant in eliciting an appropriate immune response in 
humans and animals. In late convalescent human sera, 
the major antibody response on immunoblot is against 
VP1, not VP2 (Kurtzman et al., 1989a; Schwarz et aL, 
1988). Recombinant capsids consisting only of VP2 fail 
to elicit a neutralizing immune response in animals (Kaji- 
gaya et aL, 1991), and increasing proportions of VP1 in 
capsids results in more effective antibodies for protection 
of erythroid progenitors in tissue culture (Bansal et aL, 
1992). An antiserum produced by immunization of rabbits 
with a fusion protein containing the entire unique region 
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sequence of VP1 neutralized the virus' activity; this anti- 
serum also immunoprecipitated virions and empty cap- 
sids, establishing an external localization of at least a 
portion of the unique region (Rosenfeld et aL, 1992). 
When rabbits were inoculated with 11 overlapping fusion 
proteins choser~ to span the entire VP1 capsid protein 
(therefore, including VP2), the VP1 unique and VP1-VP2 
junction regions contained the strongest neutralizing epi- 
topes (Saikawa et al., 1993). Peptides from the most 
amino-terminal par[ of the unique region most rapidly 
elicited neutralizing antibodies. By immunizing rabbits 
with overlapping synthetic peptides, neutralizing epi- 
topes in this region were identified and localized to two 
short peptides. 
We have now systematically examined synthetic pep- 
tides from the entire VP1 unique region and the VP1- 
VP2 junction region for their ability to elicit a neutralizing 
antibody response in rabbits. Our results indicate that the 
unique region contains numerous neutralizing epitopes, 
clustered in particular at the amino-terminus (between 
amino acids 1 and 80) and in the center (amino acids 
148-205); synthetic peptides representing these regions 
might be useful as a human vaccine against parvovirus 
infection. 
MATERIALS AND METHODS 
Synthetic peptides 
Thirteen overlapping peptides (MP1-MP13) corre- 
sponding to amino acids (aa) 46 to 259 of the VP1 protein 
were designed, synthesized, and formulated in a multiple 
antigenic system (Tam, 1988) (Table 1). Each peptide was 
composed of 22 aa and flanking peptides overlapped by 
6 aa. Each peptide was covalently linked to an octa- 
branched lysine matrix core. MP1-MP11 spanned the 
VP1 unique region except for the far amino-terminal re- 
gion (aa 1-45), MP12 included the VP1-VP2 junction 
region, and MP13 spanned the amino terminus of VP2. 
Immunization 
For each peptide, three rabbits were initially inoculated 
by the subcutaneous route with 1 mg/rabbit of peptide 
emulsified in complete Freund's adjuvant. Booster injec- 
tions were performed at 3, 6, 9, 12, and 14 weeks with 
0.5 mg of antigen/rabbit in incomplete Freund's adjuvant. 
Sera were obtained from phelobotomies performed at 
the time of inoculation. 
Immunoblot 
Rabbit antisera were examined for reactivity to recom- 
binant empty capsids that contained both VP1 and VP2 
B19 parvovirus capsid proteins (Kajigaya et aL, 1991). 
Empty capsids were boiled in Laemmli sample buffer and 
the sample was then subjected to 7.5% polyacrylamide 
electrophoresis (SDS- PAG E) followed by electrotransfer 
onto a nitrocellulose membrane. The membrane was 
treated with Super Block blocking buffer (Pierce, Rock- 
ford, IL) for 2 hr at room temperature and then cut into 
5-mm-wide strips. Each strip of membrane was incu- 
bated with an individual antiserum (1,1000 dilution) in 50 
mM Tris-HCI, pH 7.5, 200 mM NaCI, and 0.05% Tween 
20 (TBST) for 1 hr at room temperature. After washing 
membranes three times with TBST, primary antibodies 
were detected using alkaline phosphatase conjugated- 
goat anti-rabbit IgG in TBST by incubation for 1 hr at room 
temperature, followed by color development in a substrate 
solution containing nitroblue tetrazolium and 5-bromo-4- 
chloro-3-indolylphosphate p-toluidine salt (Gibco BRL Life 
Technologies, Gaithersburg, MD). 
ELISA 
An enzyme-linked immunosorbent assay (ELISA) was 
devised to evaluate the titer and reactivity of rabbit anti- 
sera, using recombinant empty B19 parvovirus capsids 
containing both VP1 and VP2 as antigens. The concentra- 
tion of empty capsids was adjusted to 1 #g/ml in phos- 
phate buffered saline (PBS), and 100 #l of aliquot was 
added to each well of Immulon II microtiter plates (Dyna- 
tech, Chantilly, VA), followed by incubation at 4 ° over- 
night. After blocking with Super Block blocking buffer 
(Pierce) for 2 hr at room temperature, 100 #1 of various 
dilutions of antiserum in PBS, 0.05% Tween 20 (PBST), 
were added. After incubation for 1 hr at room tempera- 
ture, plates were washed three times with PBST, incu- 
bated with 100 /~1 of peroxidase-conjugated goat anti- 
rabbit IgG (diluted 1=7500; Promega, Madison WI) for 1 
hr at room temperature. After washing with PBST, 100 #1 
of substrate solution (1-Step Slow TMB-ELISA; Pierce) 
.was added; the enzyme reaction was stopped with 100 
/~1 of 1 N H2SO4. Absorbance at 450 nm was measured by 
an automated microplate reader (Bio-Rad Laboratories, 
Hercules, CA). Nonspecific binding of antigen was deter- 
mined by substituting for antigen with 3% bovine serum 
albumin (BSA); average binding activity for BSA was 
0.081 + 0.004. Nonspecific binding of antisera was mea- 
sured using each preimmune antiserum diluted 1=1600; 
the average binding activity of preimmune sera was 0.075 
_+ 0.019. 
Erythroid colony assay 
The ability of antisera to neutralize B19 parvovirus cy- 
totoxicity was assessed in erythroid colony assays using 
human bone marrow cells. Bone marrow was obtained 
from normal donors under a protocol approved by Institu- 
tional Review Board of the National Heart, Lung, and 
Blood Institute. Mononuclear cells were isolated from 
bone marrow cells in a FicolI-Hypaque gradient (Organon 
Teknika, Durham, NO) and washed three times with Is- 
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TABLE 1 
Sequence and Location of Multiple Antigenic Peptides 
Synthetic Location 
peptide (aa) Sequence 
MP1 46-67 
M P2 62- 83 
MP3 78-99 
MP4 94-115 
MP5 110-131 
MP6 126-147 
MP7 142-163 
MP8 158-179 
MP9 174-195 
MPIO 190-211 
MP11 206-227 
MP12 222-243 
MP13 238-259 
NISLDN PLEN PSSLFDLVARIK 
LVARIKNN LKNSPDLYSH H FQS 
SHH FQSHGQLSDH PHALSSSSS 
LSSSSSHAEPRGENAVLSSEDL 
LSSEDLHKPGQVSVQLPGTNYV 
PGTNYVG PG ENLQAG PPQSAVD 
PQSAVDSAARIH DFRYSQLAKL 
SQLAKLGI N PYTHWTVAD EE LL 
ADEELLKNIKN ETGFQAQVVKD 
AQVVKDYFTLKGAAAPVAH FQG 
VAH FQGSLPEVPAYNAS EKYPS 
S EKYPS MTSVNSAEASTGAG GG 
TGAGGGGSNSVKSMWSEGATFS 
cove's modification of Dulbecco's medium containing 
10% fetal calf serum (FCS). The cells were resuspended 
in the same medium at a concentration of 2 x 108 cells/ 
ml and plated in methylcellulose. Rabbit antisera were 
incubated at 56 ° for 30 min to inactivate complement. 
Mononuclear cells (3 X 105 cells/150 #1) were incubated 
with 50 #1 of 1,10 dilution of rabbit antiserum for 1 hr at 
4 °. Thirty microliters of diluted human serum containing 
infectious B19 parvovirus was added to the cell mixture 
and allowed to incubate for another 1 hr at 4 °. The mixture 
was then cultured in standard colony culture medium for 
late erythroid progenitor cells (CFU-E)= 0.8% methylcellu- 
lose, 30% FCS, 1% BSA, and 10 mM 2-mercaptoethanol 
(Terry Fox Laboratory, Vancouver, Canada) supple- 
mented with 10 units of recombinant human erythropoie- 
tin (Ortho, Raritan, N J). Colonies were counted after 7 -8  
days of incubation at 37 ° in 6% 002 and 95% humidity. 
All colony assays were carried out in duplicate. Control 
cultures included bone marrow alone, bone marrow and 
virus, and bone marrow with a known neutralizing anti- 
body or with preimmune rabbit sera. 
RESULTS 
Detect ion  of anti-B19 parvovirus antibodies by 
immunoblot 
We synthesized 13 peptides of 22 amino acids each; 
overlapping sequences were chosen to span the VP1 
unique and VP1 -VP2 junction regions (Table 1 ). The pep- 
tides were covalently linked to a polytysine backbone to 
produce a multivalent antigen. Three rabbits were inocu- 
lated with each peptide preparation, and production of 
antibodies to denatured B19 parvovirus capsid proteins 
was examined by immunoblot. Rabbit sera were obtained 
at 12 weeks, and each of 39 sera or 13 pooled sera 
from individual groups were tested (Fig. 1). For animals 
inoculated with MP1-MP11, peptides that spanned aa 
46-227 of the VP1 unique region, antisera specifically 
recognized the VP1 protein and did not react with VP2. 
Antisera against MP12, derived from sequence of the 
VP1 -VP2 junction region, showed reactivity to both VP1 
and VP2. Antisera to M13, from within VP2, also reacted 
with both VP1 and VP2 (because VP1 contains these 
sequences). Although all the multiple antigenic peptides 
elicited an antibody response which recognized B19 cap- 
sid proteins, reactivity to VP1 protein was weak for anti- 
sera prepared against MP1 and very poor for antisera to 
MP6. When the 39 rabbit individual sera (obtained at 12 
weeks) were assayed individually by immunoblot, sera 
against MP1 and MP6 showed similar weak reactivity 
(data not shown). All antisera showed strong binding to 
the multiple antigenic peptide immunogens in the same 
immunoblot assay (data not shown). 
Binding and neutralizing activities of individual 
ant i serum 
Binding of antisera was assayed by ELISA, using 
empty but intact capsids as antigens in native conforma- 
tion. Various concentrations of the 39 antisera obtained 
from bleeding at 12 weeks were tested. Although there 
was considerable variability in the results of sera within 
each group, antisera produced by immunization with 
MP1 and MP6 peptides showed low binding (data not 
shown). Sera were also tested from animals immunized 
with one of three peptides derived from the far amino 
terminus (previously reported (Saikawa et al., 1993)), two 
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FIG. 1. Immunoblot analysis of rabbit antisera raised to MP1 to MP13. 
Recombinant VP1 + 2 empty capsids were subjected to PAGE and 
electrotransferred to nitrocellulose membranes. Immunoblot was per- 
formed using rabbit antisera obtained at 12 weeks from primary inocu- 
lation in order to examine reactivity to capsid proteins using empty 
recombinant B19 parvovirus capsids containing both major and minor 
structural protein species. Lanes 1 to 13 show results with pooled 
antisera of individual groups of sera, each group from animals immu- 
nized with one of 13 multiple antigenic peptides, MP1 to MP13. Molecu- 
lar weight markers are shown in kilodaltons (Kd) on the left. Anticipated 
positions of VP1 and VP2 are indicated by arrows. 
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rabbits were inoculated with each peptide in an identical 
protocol to that used for MP1-13; neutralization data of 
these sera were previously reported (Saikawa et aL, 
1993), all showed binding activity similar to MP1 binding 
(F1, mean binding, 0.275; F2, 0.175; F3, 0.19). 
Neutralizing activity of individual antisera were evalu- 
ated by erythroid colony assays in which human bone 
marrow cells are targets of virus infection. Antisera 
against MP1, MP2, and MP7 were highly protective of 
erythroid colony formation; antisera against MP3 and 
MP10 showed intermediate activity, and no significant 
neutralization was observed for antisera to MP4, MP6, or 
MP13 (data not shown). (For comparison, sera of animals 
inoculated with F1-F3, F3 was highly protective, one of 
two sera for F2 was protective, and F1 sera were not 
active (Saikawa et aL, 1993)). Neutralizing ability of anti- 
sera did not parallel the binding activity of sera in immu- 
noblot or ELISA. 
Sera obtained from animals at 16 weeks, after initial 
inoculation and four booster injections, were compared 
to antisera obtained at 12 weeks. Pooled antisera from 
the three animals immunized with each peptide prepara- 
tion were compared for binding and neutralizing activities 
(Fig. 2). Antisera at 16 weeks showed slightly higher 
binding activities than 12-week antisera. MP7 peptide 
appeared to be most consistently immunogenic and MP1 
and, in particular, MP6 were least immunogenic. In ery- 
throid colony assays of neutralizing activity, of the anti- 
sera obtained at 12 weeks, three (against MP1, MP2, 
and MP7) were greatly protective for erythroid progenitor 
cells, while others showed only a little or no protective 
nature. However, increased neutralizing activities were 
observed for several antisera obtained from 16 weeks= 
sera against MP3, MP8, MP9, and MP10 were more than 
50% protective, and antisera to MP5, MP6, MP11, MP12, 
and MP13 offered significant protection, preserving 20 
to 40% of colony-forming cells from cytotoxicity. For anti- 
sera to MP4, little or no neutralizing activity was apparent 
even for 16-week collections. 
Localization of neutralizing epitopes 
In an earlier study, we immunized rabbits with fusion 
proteins and found that several strong neutralizing epi- 
topes were clustered in the VP1 unique and VPI-VP2 
junction regions (Saikawa et aL, 1993). That study in- 
cluded preliminary experiments with three overlapping 
multiple antigenic peptides, there labeled F1 to F3, from 
the far amino-terminus, and we have combined data for 
F1-F3 with those obtained here using 13 overlapping 
multiple antigenic peptides as well as the larger fusion 
proteins VPFI-VPF6 (Fig. 3). In general there was the 
expected correlation of neutralizing activities (at 12 
weeks) of fusion proteins and peptides= (1) strong activity 
forVPF1 and its included four peptides, F2, F3, MP1, and 
M P2, and moderate activity for VPF2 and its two peptides, 
MP1 and MP2; (2) weak activity for VPF3, which con- 
tained only a single neutralizing peptide, MP7; (3) VPF4 
and VPF6 showed no activity and lacked neutralizing 
epitopes also on peptide immunization. However, the fu- 
sion protein VPF5 elicited highly neutralizing antisera 
while its individual constituent peptides failed to provoke 
a neutralizing antibody response. Likely conformationally 
dependent neutralizing epitopes exist in this fragment. 
Neutralizing activities of some antisera became appar- 
ent only at 16 weeks. There was no obvious correlation 
of neutralizing activity and computer-generated predic- 
tions of protein structure. 
DISCUSSION 
Although neutralizing epitopes have been localized 
within the sequence of the major capsid protein VP2 by 
analysis of binding of monoclonal antibody to synthetic 
peptides (Sato eta/., 1991a,b; Yoshimoto eta/., 199t), we 
examined the unique region of VP1, the minor capsid 
protein, because of its immunodominance in the human 
immune response. The presence of multiple neutralizing 
linear epitopes within the VP1 unique region suggests 
that recognition of this region by antibodies is not as 
conformationally fixed as for VP2 epitopes. Antibody may 
interfere with a crucial step in the virus life cycle. VP1 is 
not involved in binding of the virus to its receptor (Brown 
et al., 1993) but, by analogy with poliovirus (Lee et al., 
1993) and adenovirus 2 (Greber et al., 1993), perhaps 
participates in unpackaging of genetic material. 
Although a variety of immunologic data show that the 
unique region of VP1 is clearly externally presented, its 
precise relationship to the capsid is unknown. Neither 
VP1, which constitutes only a small portion of the virus 
structure, nor the most amino-terminal 38 aa of VP2 were 
visualized in crystals of canine parvovirus (Tsao et aL, 
1991). Binding of an antipeptide antibody to virus indi- 
cates that the immunogen must correspond to a surface 
region of the protein and therefore of the virus. By this 
criterion, we can infer from our peptide sera experiments 
that much of the unique region of VP1 is external. Low 
binding activity was only detected for four peptides from 
the far amino terminus (F1 -F3 (8aikawa eta/., 1993) and 
MP1), suggesting that the first approximately 70 amino 
acids of the unique region of VP1 may be relatively inter- 
nal in the tertiary structure of native capsid (interpretation 
of the poor binding of MP6 is more problematic as this 
peptide did not elicit a strong antibody response to dena- 
tured capsid proteins). 
Despite the absence of an animal model, in many re- 
spects the immune response to B19 parvovirus is better 
understood than immunity to other Parvoviridae. Results 
of experiments with canine parvovirus are of interest be- 
cause the structure of this virus has been solved to less 
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FIG. 2. Comparison of binding and neutralizing activities of 12- and 16-week antisera. Antisera of three rabbits belonging to each group pooled. 
Binding activities of the pooled antisera at 12 weeks (A) and 16 weeks (B) were measured by ELISA using recombinant VP1 + 2 empty capsids. 
The pooled sera were diluted to two different concentrations (1=400 and 1:1600); OD values at 450 nm for the high-titer sera are not linear at a 
dilution of 1=400 (closed bars) but are linear at 1:1600 (dotted bar). Each bar represents a mean value _+ standard error for OD at 450 nm of two 
independent experiments. Neutralizing activity of pooled antisera at 12 weeks (C) and 16 weeks (D) were determined by erythroid colony assays. 
Results are expressed as percentages of erythroid colony numbers of the uninfected control. Each bar indicates a mean value _+ SE of at least 
three independent experiments. Control cultures with uninfected bone marrow cells in the experiments shown in (C) or (D) yielded 39 +_ 7 or 51 
_+ 11 erythroid colonies/105 bone marrow cells, respectively. 
than 3-A, resolution (Tsao eta/., 1991). For example, pep- 
tide mapping of antisera and monoclonal antibodies us- 
ing nonapeptide sets indicated that the amino terminus 
of VP2 was an immunogenic domain and capable of 
eliciting neutralizing antibodies (Langeveld et al., 1993), 
while fusion proteins from the carboxyl terminus were 
not effective in eliciting a neutralizing antibody response 
(Lopez de Turiso et al., 1991). Two neutralizing epitopes 
were localized in loops 1 and 3 on the virion surface and 
therefore accessible to antibody binding (Langeveld et 
al., 1993). 
Fusion proteins derived from cloned canine parvovirus 
have been used as immunogens (Lopez de Turiso et 
aL, 1991). Neutralizing monoclonal antibodies recognized 
canine VP2 only, but fusion proteins from the VP2 se- 
quence, while immunogenic, were minimally protective 
of virus infection in vitro; in contrast, a peptide that con- 
tained 42 codons of VP1 unique region and the first 22 
codons of VP2 elicited a VPl-specific antibody response 
in rabbits, and these sera neutralized canine parvovirus 
in vitro (Lopez de Turiso etaL, 1991). At least one canine 
T cell clone obtained after immunization with virus recog- 
nized VP1 specifically (Rimmelzwaan et al., 1990). Re- 
cently, protective vaccination of dogs with synthetic pep- 
tides was reported: the immunogen was two peptides 
15 amino acids long, derived from the amino terminus 
of the major capsid protein (Langeveld et aL, 1994) (a 
region perhaps analogous to the B19 VP1-VP2 junction 
region). Extrapolation from canine parvovirus to B19 par- 
vovirus is limited by major differences in the structure 
and biology of these two viruses. 
However, by X-ray crystallographic studies, the major 
spike is absent from B19 parvovirus empty capsids (Ag- 
bandje et al., 1991). Empty canine parvovirus capsids 
composed of VP2 only were protective in dog vaccine 
trials (L6pez de Turiso et aL, 1992), but a neutralizing 
antibody response to B19 parvovirus empty capsids re- 
quires the presence of VP1 (Kajigaya et aL, 1991; Bansal 
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FIG. 3. Summary of neutralizing activities of fusion and synthetic 
peptides. The ability of multiple antigenic peptides (MP1 to MP13) to 
elicit neutralizing activities for B19 parvovirus are compared to activity 
of fusion proteins (VPF1 to VPF6) and multiple antigenic peptides (F1 
to F3)which were reported elsewhere (Saikawa eta/., 1993). Neutraliza- 
tion as evaluated by erythroid colony assay were expressed as percent- 
ages of control colony numbers and scored as follows, 0-20% (-);  21 - 
40% (+); 41-60% (+), 61-80% (++); 81-100% (+ + +). For MP1 -MP13, 
data obtained from both 12- and 16-week antisera are shown; for VPF1 - 
VPF6 and F1-F3, only 12-week antisera were tested. 
et a/., 1992). Nevertheless, we can tentatively infer from 
the current experiments in rabbits that a single multiva- 
lent peptide or a mixture of such synthetic peptides de- 
rived from the unique region of VP1 would be an effective 
immunogen to protect humans against parvovirus infec- 
tion. Further work to examine dosage and schedule of 
inoculation is required to determine the practicality of 
such an approach. 
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